Patent Application
20250189532
The present application relates to a 1,6-diynes compound, its preparation method, and products obtained from 1,6-diynes as raw material and their applications, belonging to the field of organic synthesis.
Polycyclic compounds are widely found in natural products, pharmaceuticals, and materials. Due to their large conjugated structures and good luminescent properties, polycyclic compounds have extensive applications in the field of luminescent materials. Therefore, the synthesis methods and application studies of polycyclic compounds have attracted the attention of organic synthesis chemists. Currently, there are two main approaches to synthesizing polycyclic compounds: 1. Further modification of existing cyclic compounds to obtain the desired structure; 2. Utilizing highly unsaturated compounds such as 1,n-alkynes, 1,n-dienes, and 1,n-diynes to undergo cyclization reactions under certain conditions to construct polycyclic compounds. The former has higher specificity but requires prior design and synthesis of substrates. The latter is more efficient and can construct multiple chemical bonds simultaneously.
1,6-Diynes are a type of highly unsaturated compound containing two carbon-carbon triple bonds, which can synergistically act during reactions, allowing for various tandem cyclization reactions and exhibiting diverse reaction properties to yield different structural cyclic compounds. The synthesis of 1,6-diynes is simple, as structurally diverse 1,6-diynes can be synthesized through simple nucleophilic attacks, substitutions, or couplings of alkyne molecules. Under the influence of electrophilic reagents, transition metals, or bases, 1,6-diynes can undergo different pathways to obtain structurally diverse polycyclic compounds. In other words, the structure of 1,6-diynes themselves is diverse, and the products also exhibit diversity under different reaction conditions. Therefore, 1,6-diynes are a very useful class of organic synthesis intermediates.
According to a first aspect of the present application, a compound represented by a general formula (I) is provided. The 1,6-diyne is a type of compound with structural diversity and can be used as an important compound to synthesize compounds with great application value in fluorescent materials.
A compound represented by a general formula (I), and its tautomers, polymorphs, solvates, or salts thereof,
Optionally, the substituents in the substituted C6-C30 aryl and the substituted C3-C30 heteroaryl are selected from alkyl, alkenyl, aldehyde, halogen, haloalkyl, ester-inserted alkyl, alkoxy, alkylthio, and substituted amino.
Optionally, the substituents in the substituted C6-C30 aryl and the substituted C3-C30 heteroaryl are selected from C1-C30 alkyl, C1-C30 alkenyl, C1-C30 aldehyde group, halogen, halogenated C1-C30 alkyl, ester-inserted C1-C30 alkyl, C1-C30 alkoxy, C1-C30 alkylthio, and phenyl-substituted amino.
Optionally, wherein R′ is selected from C6-C30 aryl, C6-C10 alkyl-substituted C6-C30 aryl, C6-C30 aryl substituted with “halogen substituted C6-C10 alkyl”, C3-C30 heteroaryl, C6-C10 alkyl substituted C3-C30 heteroaryl, C3-C30 heteroaryl substituted with “halogen substituted C6-C10 alkyl”.
Optionally, R′ is selected from C6-C30 aryl, C3-C30 heteroaryl
Optionally, R1a, R4a are independently selected from hydrogen, aryl, alkyl-substituted C6-C30 aryl, C6-C30 aryl substituted with “S atom-inserted alkyl”, C6-C30 aryl substituted with “0 atom-inserted alkyl”, halogen-substituted C6-C30 aryl, aryl-substituted C6-C30 aryl, C6-C30 aryl substituted with “halogen-substituted alkyl”, C6-C30 aryl substituted with “aryl-substituted amino”, C6-C30 aryl substituted with “ester-inserted alkyl”, and C3-C30 heteroaryl.
Optionally, R1a is independently selected from phenyl, tert-butyl substituted phenyl, CH3S-substituted phenyl, CH3O-substituted phenyl, naphthyl, phenyl-substituted phenyl, phenyl substituted with at least one methyl, CF3O-substituted phenyl, Br-substituted phenyl, phenyl substituted with “diphenyl-substituted amino”, phenyl substituted with “ester-inserted methyl”, dibenzothienyl.
Optionally, R2a is selected from C6-C30 aryl, C6-C30 aryl substituted with “ester-inserted alkyl”, alkyl-substituted C6-C30 aryl, C6-C30 aryl substituted with “oxygen atom-inserted alkyl”, aryl-substituted C6-C30 aryl, C3-C30 heteroaryl, aldehyde-substituted C6-C30 aryl, halogen-substituted C6-C30 aryl, and alkenyl-substituted C6-C30 aryl.
Optionally, R2a is selected from phenyl, naphthyl, phenyl substituted with “ester-inserted methyl”, propyl-substituted phenyl, phenanthrenyl, phenyl substituted with “oxygen atom-inserted methyl”, biphenyl, thienyl, formaldehyde-substituted phenyl, Cl-substituted phenyl, vinyl-substituted phenyl.
Optionally, R3a is selected from hydrogen atom, deuterium atom, C6-C30 aryl, C6-C30 aryl substituted with “ester-inserted alkyl”, C6-C30 aryl substituted with at least one alkyl.
Optionally, R3a is selected from a hydrogen atom, a deuterium atom, phenyl, phenyl substituted with “ester-inserted methyl”, and phenyl substituted with at least one methyl.
Optionally, the tautomers have the general formula (II), the general formula (III) or the general formula (IV):
Optionally, the compound represented by formula (I) is selected from at least one of the following compounds.
Optionally, the 1,6-diyne compound is used in preparation of mitochondrial fluorescence probes for mouse fibroblasts.
Optionally, the 1,6-diyne compound is used in preparation of mitochondrial fluorescence probes for mouse mononuclear macrophage leukemia cells or HER2-breast cancer overexpressing cells, or human liver cancer cell lines.
Optionally, the 1,6-diyne compound is used to detect the absence of enzymes in the respiratory chain.
The compound of the general formula (I) is used to detect substances containing active oxygen.
Optionally, the active oxygen includes at least one of sodium hypochlorite, hydrogen peroxide, or ozone.
Optionally, the compound represented by the general formula (I) is applied to a carrier such as a silica gel plate, a ceramic sheet, a polytetrafluoroethylene sheet, a sapphire substrate, a glass or a silicon dioxide substrate, and then a compound containing active oxygen (sodium hypochlorite, hydrogen peroxide, ozone, etc.) is dripped onto the carrier. The carrier is then heated for 30 seconds. The carrier will change from colorless to red, and under 365 nm ultraviolet light, the fluorescence will gradually change from no fluorescence to strong fluorescence.
According to another aspect of the present application, a method for preparing the compound represented by the general formula (I) is provided.
The preparation method of the above-mentioned compound comprises the following steps:
Optionally, a molar ratio of the compounds represented by the general formula (V) and the general formula (VI) is in a range from 1:1 to 1:5.
Optionally, the reaction is carried out in the presence of an acid reagent; the acid reagent includes p-toluenesulfonic acid, phenylsulfonic acid, p-nitrobenzenesulfonic acid, methanesulfonic acid, ferric chloride, or aluminum trichloride.
Optionally, the reaction temperature is in a range from 25° C. to 100° C.; the reaction time is in a range from 0.1 h to 48 h.
Optionally, the preparation method of the compound represented by the general formula (V) includes the following steps:
Optionally, a molar ratio of the compounds represented by the general formula (VII) and the general formula (VIII) is in a range from 1:1 to 1:5.
Optionally, the reaction is carried out in the presence of a nucleophilic substitution reagent; the nucleophilic substitution reagent includes n-butyllithium, sec-butyllithium, tert-butyllithium, methyllithium, diisopropylamino lithium, and bis(trimethylsilyl)amino lithium.
Optionally, the reaction temperature is in a range from −78° C. to 50° C.; the reaction time is in a range from 0.1 h to 24 h.
As an embodiment, the preparation method of the compound contains the following steps:
According to another aspect of the present application, a 3-arylbenzisoisoindole compound and its tautomers, polymorphs, solvates, or salts thereof are provided.
A 3-arylbenzisoisoindole compound and its tautomers, polymorphs, solvates, or salts thereof, wherein the 3-arylbenzisoisoindole compound has the structural formula described in formula (A):
According to another aspect of the present application, a preparation method of the 3-arylbenzisoisoindole compound represented by the general formula (IX) comprises the following steps:
Optionally, the base is at least one selected from cesium carbonate, potassium carbonate and sodium carbonate.
Optionally, the structural formula of the compound represented by the 3-arylbenzisoisoindole compound represented by the general formula (IX) is selected from the following compounds:
Optionally, the organic solvent I is at least one selected from methanol, isopropyl alcohol, n-butanol, toluene and xylene.
Optionally, a molar ratio of the 1,6-diyne compound to the base is in a range from 1:0.1 to 1:10.
Optionally, a concentration of the 1,6-diyne compound is in a range from 20 mM to 1M.
Optionally, the molar ratio of the 1,6-diyne compound to the base is in a range from 1:1 to 1:10.
Optionally, conditions for the reaction III are as follows: reaction temperature is in a range from 25° C. to 150° C.; reaction time is in a range from 0.5 h to 72 h.
Optionally, the reaction atmosphere is an inert gas.
According to another aspect of the present application, a benzisoindole dimer compound is provided.
A benzisoindole dimer compound, wherein the benzisoindole dimer compound has the structure shown in the following formula (X):
Optionally, the benzisoindole dimer compound has a structure shown in general formula (XI);
Optionally, R101, R102, R103, R104, R105, R106, R107, R108, R109, R110, R111, R112, R113, R114, R115, R116, R117, R118, R119, R120, R121, R122 are independently selected from hydrogen atom, C1-C15 alkyl, halogen-substituted C1-C15 alkyl, aryl-substituted C1-C15 alkyl, S-inserted C1-C15 alkyl, O-inserted C1-C15 alkyl, ester-inserted C1-C15 alkyl, C1-C15 alkenyl, C6-C30 aryl, alkyl-substituted C6-C30 aryl, C3-C30 heteroaryl, substituted C3-C30 heteroaryl, and optionally inserted at any position by the following heteroatom groups: CO, O, S, SO, SO2, N, NRa, —N═, =N—; any two adjacent groups among R101, R102, R103, R104, R105, R106, R107, R108, R109, R110, R111, R112, R113, R114, R115, R116, R117, R118, R119, R120, R121, R122 can form a ring;
Optionally, the benzisoindole dimer compound has a structure shown in general formula (XII);
Optionally, R201, R202, R203, R204, R205, R206, R207, R208, R209, R210, R211, R212, R213, R214, R215, R216, R217, and R218 are independently selected from hydrogen atom, C1-C15 alkyl, halogen-substituted C1-C15 alkyl, aryl-substituted C1-C15 alkyl, S-inserted C1-C15 alkyl, O-inserted C1-C15 alkyl, ester-inserted C1-C15 alkyl, C1-C15 alkenyl, C6-C30 aryl, alkyl-substituted C6-C30 aryl, C3-C30 heteroaryl, substituted C3-C30 heteroaryl, and optionally inserted at any position by the following heteroatom groups: CO, O, S, SO, SO2, N, NRa, —N═, =N—; any two adjacent groups among R201, R202, R203, R204, R205, R206, R207, R208, R209, R210, R211, R212, R213, R214, R215, R216, R217, and R218 can form a ring;
According to another aspect of the present application, a method for preparing a benzisoindole dimer compound contains the following steps:
Optionally, the oxidant is at least one selected from 2,2,6,6-tetramethylpiperidine nitrogen oxide, oxygen, sodium hypochlorite, aqueous hydrogen peroxide solution, tert-butanol peroxide, lauroyl peroxide, benzoyl peroxide, tert-butyl perbenzoate, m-chloroperoxybenzoic acid, peracetic acid, and di-tert-butyl peroxide.
Optionally, the organic solvent II is at least one selected from methanol, ethanol, isopropanol, p-xylene, n-butanol, ethyl acetate, acetonitrile, N,N-dimethylformamide and dimethyl sulfoxide.
Optionally, conditions for reaction II are as follows: reaction temperature is in a range from 25° C. to 150° C.; reaction time is in a range from 0.5 h to 72 h.
According to another aspect of the present application, use of the compound represented by the general formula (I) and/or the compound obtained by the preparation method in the preparation of mitochondrial fluorescent probes, in the detection of substances containing active oxygen and in cell imaging are provided.
Optionally, the method for preparing the mitochondrial fluorescent probe contains the following steps:
Optionally, volume of a solution of the 1,6-diyne compound is in a range from 1 μL to 1000 μL.
Optionally, concentration of a solution of the 1,6-diyne compound is in a range from 1 μM to 1000 μM.
Optionally, conditions for incubation are as follows:
Optionally, the compound represented by the general formula (I) is used in preparation of mitochondrial fluorescent probes of mouse fibroblasts.
Optionally, the compound represented by the general formula (I) is used in preparation of mitochondrial fluorescent probes for mouse mononuclear macrophage leukemia cells or HER2-breast cancer overexpression cells or human liver cancer cell lines.
Optionally, the active oxygen includes at least one of sodium hypochlorite, hydrogen peroxide, and ozone.
According to another aspect of the present application, use of the 3-arylbenzoisoindole compound obtained by the preparation method and/or the 3-arylbenzoisoindole compound and its tautomers, polymorphs, solvates, or their salts in lysosomal fluorescent probe, autophagy lysosome fluorescent probe, synthesis of benzisoindole dimer compound, optical super-resolution microscopy, confocal microscopy, wide-field microscopy, fluorescence lifetime imaging microscopy, fluorescence resonance energy transfer microscopy, super-resolution optical wave imaging, fluorescence activation localization microscopy, and light-emitting device are provided.
According to another aspect of the present application, use of the benzisoindole dimer compound obtained by the preparation method according to any one of claims 29 to 32 and/or the benzisoindole dimer compound according to any one of claims 33 to 37 in mitochondrial fluorescence probes, optical super-resolution microscopy, confocal microscopy, wide-field microscopy, fluorescence lifetime imaging microscopy, fluorescence resonance energy transfer microscopy, super-resolution optical fluctuation imaging, fluorescence photoactivated localization microscopy, light-emitting devices, cellular imaging, and fluorescent dyes are provided.
Optionally, the benzisoindole dimer compound is produced by the compound represented by the general formula (I) according to any one of claims 1 to 12 during cell incubation.
Optionally, excitation wavelength of the benzisoindole dimer compound is in a range from 220 nm to 1000 nm.
Optionally, emission wavelength of the benzisoindole dimer compound is in a range from 400 nm to 800 nm.
In the present application, “alkyl” refers to a group obtained by losing a H atom from an alkane.
“Alkenyl” refers to a group obtained by losing a H atom from an alkene.
“Alkynyl” refers to a group obtained by losing a H atom from an alkyne.
“Cycloalkyl” refers to a group obtained by losing a H atom from a cycloalkane.
“Heterocycloalkyl” refers to a group obtained by losing a H atom from a heterocycloalkane.
“Aryl” refers to a group obtained by losing a H atom from an aromatic hydrocarbon.
“Heteroaryl” refers to a group obtained by losing a H atom from a heteroaromatic hydrocarbon.
“Substituted alkyl,” “substituted aryl,” and the like refer to alkyl substituted with any group, and aryl substituted with any group, respectively.
“inserted at any position by heteroatom groups” means that heteroatom groups can be inserted into the group by replacing a hydrogen atom or a carbon atom, for example, “O-inserted methyl is CH3O—”, “S-inserted methyl is CH3S—”, “NH inserted methyl group is CH3NH—” and “N-inserted phenyl is a pyridyl”, etc.
“Alkyl-substituted aryl”, “aryl-substituted aryl” and the like respectively represent aryl containing alkyl substituent(s) and aryl containing aryl substituent(s), for example
etc.; wherein “*” represents the connection point of the group.
In the present application, unless otherwise specified, “alkyl”, “aryl” and the like may have any number of connection points; generally, there may be 1, 2, 3, 4, or 5 connection points.
“C1-C30” refers to the number of carbon atoms.
“Halogen-substituted C1-C30 alkyl” refers to an alkyl group having 1 to 30 carbon atoms and substituted with halogen carbon atoms is between 1 and 30.
“Halogen” refers to fluorine, chlorine, bromine, and iodine.
“optionally inserted at any position by a heteroatom group selected from the following: CO, O, S, SO, SO2, N, NRa, —N═, =N—” means that the heteroatom group can be inserted at any position under the premise of satisfying the valence bond rules, for example, between any C—C, C—S, C—O, or O—O bonds.
“Salt” refers to acidic and/or basic salts formed with inorganic and/or organic acids and bases. Furthermore, when the compound in the present application contains a basic moiety (such as, but not limited to, pyridine or imidazole) and an acidic moiety (such as, but not limited to, carboxylic acid), zwitterions (“inner salts”) may form and are included in the term “salt” as used herein.
“Solvate” includes, for example, hydrates.
The structural formulas described in the present application are intended to include all isomeric forms (such as enantiomers, diastereomers, and geometric isomers (or conformational isomers)): for example, R—S configurations with asymmetric centers, and (Z), (E) isomers of double bonds, etc. Therefore, single stereochemical isomers or mixtures of enantiomers, diastereomers or geometric isomers (or conformational isomers) of the compounds in the present application are within the scope of the present application.
“Tautomers” refer to structural isomers with different energies that can interconvert by overcoming low energy barriers. For example, proton tautomers (i.e., prototropic) include interconversions by migration of a proton. Valence tautomers include interconversions by reorganization of some of the bonding electrons.
“Solvate” refers to a complex formed by the coordination of the compound in the present application with solvent molecule(s) in a specific ratio.
The beneficial effects that can be achieved by this application include:
The present application is described in detail below with reference to the Examples, but the present application is not limited to these Examples.
Unless otherwise specified, the raw materials and catalysts in the Examples of the present application are purchased through commercial channels.
Among them, IPA refers to isopropanol; nBuOH refers to n-butanol; p-xylene refers to para-xylene.
The analytical methods in the Examples of the present application are as follows:
Nuclear magnetic resonance analysis is performed using Bruker-BioSpin AVANCE III HD and JEOL ECZ600S instruments.
Mass spectrometry analysis is performed using a Thermo Fisher Scientific LTQ FTICR-MS instrument.
Cell fluorescence labeling analysis is performed using a Zeiss LSM 880 confocal fluorescence microscope.
Ultraviolet-visible absorption and emission spectrum analysis is performed using a Shimadzu UV-1900 and an Edinburgh FS5-NIR.
Cyclic voltammetry analysis is performed using a Shanghai Chenhua electrochemical analyzer.
Hank's buffer solution consists of 1.26 mM CaCl2), 0.49 mM MgCl2, 0.41 mM MgSO4, 5.33 mM KCl, 0.44 mM KH2PO4, 4.17 mM NaHCO3, 138 mM NaCl, 0.34 mM Na2HPO4, 5.55 mM glucose, pH=7.4.
Silent siRNA (cytc-290, cytc-436) is purchased from Suzhou GenePharma Co., Ltd.
The calculation formulas for the yields of compound IM-(1˜9) and dimeric compound FL-(1-9) in the Examples of the present application are as follows:
Yield of compound IM-(1-9)=(molar mass of product/molar mass of raw material)*100%.
Yield of dimeric compound FL-(1-9)=(molar mass of product/molar mass of raw material)*2*100%.
The compounds in Table 1 are prepared by the following method:
In a dry 50 mL round-bottom flask equipped with a stirrer, phenylacetylene (5 mmol, 1 equiv.) and 10 mL of tetrahydrofuran are added. The round-bottom flask is cooled to −78° C. under an inert gas atmosphere, and then n-butyllithium (2.5 M in THF, 2 mL, 5 mmol, 1 equiv.) is slowly added dropwise. The reaction is allowed to return to room temperature and stirred for 30 minutes, then cooled again to −78° C. Benzaldehyde (5 mmol, 1 equiv.) is dissolved in tetrahydrofuran and slowly added to the reaction mixture. After the addition is complete, the reaction is returned to room temperature and stirred for 30 minutes. After the reaction is complete, the reaction is quenched with saturated ammonium chloride aqueous solution, and the aqueous phase is extracted three times with ethyl acetate. The organic phases are combined, dried over magnesium sulfate, filtered, and spin-dried to obtain a crude product of propargyl alcohol.
The crude product of propargyl alcohol and N-propargyl benzenesulfonamide (6 mmol, 1.2 equiv.) are dissolved in 10 mL of dichloromethane under an inert gas atmosphere·TsOH H2O (0.5 mmol, 10 mol %) is then added, and the reaction is heated to reflux overnight. After the reaction is complete, the reaction is quenched with a saturated aqueous solution of NaHCO3, and the aqueous phase is extracted three times with ethyl acetate. The organic phases are combined, dried over magnesium sulfate, filtered, and spin-dried to obtain the crude product of propargyl alcohol. The crude product is purified by silica gel column chromatography to yield MP-1 (yield 57%).
The preparation method of PA-2 compound is similar to that of PA-1, except that N-propargylbenzenesulfonamide is replaced with the following structure
The preparation method of the PA-3 compound is similar to that of the PA-1 compound, except that phenylacetylene is replaced by 4-methoxyphenylacetylene.
The preparation method of the PA-4 compound is similar to that of the PA-1, except that phenylacetylene is replaced by 4-chlorophenylacetylene, and benzaldehyde is replaced by 4-decyloxybenzaldehyde.
The preparation method of PA-5 compound is similar to that of PA-1, except that N-propargylbenzenesulfonamide is replaced with the following structure
The preparation method of PA-6 compound is similar to that of PA-1, except that benzaldehyde is replaced by 4-phenylbenzaldehyde and N-propargylbenzenesulfonamide is replaced by the following structure
The preparation method of PA-7 compound is similar to that of PA-1, except that benzaldehyde is replaced by 2-naphthaldehyde and N-propargylbenzenesulfonamide is replaced by the following structure
The preparation method of PA-8 compound is similar to that of PA-1, except that benzaldehyde is replaced by 4-methoxyformaldehyde.
The preparation method of PA-9 compound is similar to that of PA-1, except that benzaldehyde is replaced by 4-methoxyformaldehyde and N-propargylbenzenesulfonamide is replaced by the following structure
The preparation method of the PA-10 compound is similar to that of the PA-1 compound, except that benzaldehyde is replaced by thiophene-2-carboxaldehyde.
The preparation method of the PA-11 compound is similar to that of the PA-1 compound, except that phenylacetylene is replaced by 4-formylphenylacetylene.
The preparation method of the PA-12 compound is similar to that of the PA-1 compound, except that benzaldehyde is replaced by 4-tert-butylbenzaldehyde.
The preparation method of the PA-13 compound is similar to that of the PA-1 compound, except that benzaldehyde is replaced by 4-methylthiobenzaldehyde.
The preparation method of the PA-14 compound is similar to that of the PA-1 compound, except that benzaldehyde is replaced by 4-bromobenzaldehyde.
The preparation method of the PA-15 compound is similar to that of the PA-1 compound, except that phenylacetylene is replaced by 4-phenylphenylacetylene.
The preparation method of the PA-16 compound is similar to that of the PA-1 compound, except that phenylacetylene is replaced by 2-naphthylacetylene.
The preparation method of PA-17 compound is similar to that of PA-1, except that benzaldehyde is replaced by 4-phenylbenzaldehyde.
The preparation method of the PA-18 compound is similar to that of the PA-1 compound, except that benzaldehyde is replaced by 2,6-dimethylbenzaldehyde
The preparation method of PA-19 compound is similar to that of PA-1, except that benzaldehyde is replaced by 2,6-dimethylbenzaldehyde and N-propargylbenzenesulfonamide is replaced by the following structure
The preparation method of the PA-20 compound is similar to that of the PA-1 compound, except that benzaldehyde is replaced by 2-phenylbenzaldehyde.
The preparation method of the PA-21 compound is similar to that of the PA-1 compound, except that benzaldehyde is replaced by 4-phenylbenzaldehyde, and phenylacetylene is replaced by 4-propylphenylacetylene.
The preparation method of PA-22 compound is similar to that of PA-1, except that benzaldehyde is replaced by 4-methylthiobenzaldehyde and N-propargylbenzenesulfonamide is replaced by the following structure
The preparation method of PA-23 compound is similar to that of PA-1, except that N-propargylbenzenesulfonamide is replaced with the following structure
The preparation method of PA-24 compound is similar to that of PA-1, except that benzaldehyde is replaced by 2-phenylbenzaldehyde and N-propargylbenzenesulfonamide is replaced by the following structure
The preparation method of the PA-25 compound is similar to that of the PA-1 compound, except that phenylacetylene is replaced by 4-chlorophenylacetylene.
The preparation method of PA-26 compound is similar to that of PA-1, except that benzaldehyde is replaced by 1-naphthaldehyde.
The preparation method of PA-27 compound is similar to that of PA-1, except that N-propargylbenzenesulfonamide is replaced with the following structure
The preparation method of PA-28 compound is similar to that of PA-1, except that benzaldehyde is replaced by 4-decyloxyformaldehyde, phenylacetylene is replaced by 4-chlorophenylacetylene, and N-propargylbenzenesulfonamide is replaced by the following structure
The preparation method of the PA-29 compound is similar to that of the PA-1 compound, except that phenylacetylene is replaced by 4-propylphenylacetylene.
The preparation method of the PA-30 compound is similar to that of the PA-1 compound, except that phenylacetylene is replaced by 2-naphthyleneacetylene.
The preparation method of PA-31 compound is similar to that of PA-1, except that N-propargylbenzenesulfonamide is replaced with the following structure
The preparation method of PA-32 compound is similar to that of PA-1, except that benzaldehyde is replaced by 4-methoxybenzaldehyde and N-propargylbenzenesulfonamide is replaced by the following structure
The preparation method of the PA-33 compound is similar to that of the PA-1 compound, except that phenylacetylene is replaced by 4-methoxycarbonylphenylacetylene.
The preparation method of the PA-34 compound is similar to that of the PA-1 compound, except that phenylacetylene is replaced by 9-ethynylphenanthrene.
The preparation method of the PA-35 compound is similar to that of the PA-1 compound, except that benzaldehyde is replaced by 4-diphenylaminobenzaldehyde.
The preparation method of PA-36 compound is similar to that of PA-1, except that N-propargylbenzenesulfonamide is replaced with the following structure
The preparation method of the PA-37 compound is similar to that of the PA-1 compound, except that benzaldehyde is replaced by 4-formyldibenzothiophene.
The preparation method of PA-38 compound is similar to that of PA-1, except that benzaldehyde is replaced by 4-trifluoromethylbenzaldehyde.
The preparation method of the PA-39 compound is similar to that of the PA-1 compound, except that benzaldehyde is replaced by 4-vinylbenzaldehyde.
The preparation method of the PA-40 compound is similar to that of PA-1, except that phenylacetylene is replaced with 2,3,4,5,6-pentadeuterated phenylacetylene.
The results of the NMR test are shown in the following table:
1H NMR (600 MHz, Chloroform-d) δ 8.09-8.02 (m, 2H), 7.72-7.66 (m, 2H), 7.58-7.54 (m, 1H), 7.51-7.48 (m, 2H), 7.41-7.37 (m, 2H), 7.37-7.33 (m, 1H), 7.33-7.29 (m, 1H), 7.28-7.25 (m, 2H), 7.20-7.17 (m, 2H), 6.32 (s, 1H), 4.13 (dd, J = 18.4, 2.6 Hz, 1H), 3.75 (dd, J = 18.4, 2.5 Hz, 1H), 1.89 (t, J = 2.5 Hz, 1H).
1H NMR (600 MHz, CDCl3) δ 8.09 (d, J = 7.2 Hz, 2H), 7.80-7.72 (m, 4H), 7.52 (t, J = 7.4 Hz, 1H), 7.48-7.38 (m, 4H), 7.35 (t, J = 7.4 Hz, 1H), 7.30-7.22 (m, 1H), 7.18- 7.10 (m, 4H), 6.92 (d, J = 8.5 Hz, 2H), 6.39 (s, 1H), 4.43 (d, J = 18.5 Hz, 1H), 3.99 (d, J = 18.5 Hz, 1H), 3.88 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 166.59, 139.60, 135.77, 132.93, 131.77, 131.56, 129.39, 129.11, 128.87, 128.83, 128.78, 128.36, 128.28, 128.27, 127.26, 121.96, 89.04, 87.03, 84.25, 83.20, 53.73, 52.34, 34.64.
1H NMR (600 MHz, CDCl3) δ 8.06-8.03 (m, 2H), 7.72- 7.65 (m, 2H), 7.58-7.54 (m, 1H), 7.51-7.47 (m, 2H), 7.40- 7.33 (m, 3H), 7.12 (d, J = 8.9 Hz, 2H), 6.78 (d, J = 8.9 Hz, 2H), 6.29 (s, 1H), 4.11 (dd, J = 18.4, 2.6 Hz, 1H), 3.80 (s, 3H), 3.75 (dd, J = 18.4, 2.5 Hz, 1H), 1.88 (t, J = 2.5 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ 139.36, 135.88, 133.06, 132.95, 132.91, 128.79, 128.67, 128.63, 128.38, 128.30, 114.27, 113.91, 88.79, 81.80, 78.30, 72.66, 55.39, 53.94, 33.83.
1H NMR (600 MHz, CDCl3) δ 8.06-8.00 (m, 2H), 7.57- 7.51 (m, 3H), 7.50-7.44 (m, 2H), 7.23 (d, J = 8.7 Hz, 2H), 7.08 (d, J = 8.6 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 6.24 (s, 1H), 4.13 (dd, J = 18.5, 2.5 Hz, 1H), 3.95 (t, J = 6.6 Hz, 2H), 3.71 (dd, J = 18.5, 2.5 Hz, 1H), 1.90 (t, J = 2.5 Hz, 1H), 1.80-1.75 (m, 2H), 1.46-1.41 (m, 2H), 1.29-1.23 (m, 13H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 159.62, 139.44, 134.75, 132.80, 132.71, 129.62, 128.75, 128.70, 128.31, 127.00, 120.74, 114.56, 87.30, 84.82, 78.33, 68.21, 53.17, 33.52, 31.99, 29.67, 29.66, 29.49, 29.42, 29.38, 29.31, 26.16, 22.78, 14.23.
1H NMR (600 MHz, CDCl3) δ 8.15-8.10 (m, 2H), 7.88 (d, J = 8.3 Hz, 1H), 7.80-7.77 (m, 2H), 7.75 (d, J = 7.7 Hz, 1H), 7.71 (d, J = 8.2 Hz, 1H), 7.47-7.44 (m, 1H), 7.43- 7.37 (m, 5H), 7.36-7.27 (m, 3H), 7.22-7.18 (m, 2H), 7.12- 7.06 (m, 5H), 6.43 (s, 1H), 4.58 (d, J = 18.4 Hz, 1H), 4.15 (d, J = 18.5 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ 139.68, 135.90, 133.22, 132.98, 132.84, 131.81, 130.84, 128.89, 128.80, 128.78, 128.67, 128.66, 128.43, 128.25, 128.12, 128.08, 126.62, 126.37, 126.33, 124.94, 122.02, 120.30, 88.90, 88.71, 83.47, 83.14, 53.81, 35.02.
1H NMR (600 MHz, CDCl3) δ 8.12-8.07 (m, 2H), 7.83- 7.78 (m, 2H), 7.61 (d, J = 8.4 Hz, 2H), 7.57-7.55 (m, 2H), 7.52 (d, J = 7.5 Hz, 1H), 7.48-7.43 (m, 4H), 7.36 (t, J = 7.4 Hz, 1H), 7.28-7.25 (m, 1H), 7.20-7.14 (m, 5H), 7.06 (t, J = 7.9 Hz, 2H), 6.90 (d, J = 9.2 Hz, 2H), 6.42 (s, 1H), 4.42 (d, J = 18.4 Hz, 1H), 4.08 (d, J = 18.4 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ 141.65, 140.59, 139.62, 134.94, 132.83, 131.82, 131.66, 128.90, 128.86, 128.71, 128.25, 128.21, 128.10, 127.96, 127.61, 127.42, 127.27, 122.56, 122.06, 88.96, 85.03, 83.83, 83.24, 53.54, 34.82.
1H NMR (600 MHz, CDCl3) δ 8.24 (s, 1H), 8.17-8.10 (m, 2H), 7.90-7.81 (m, 4H), 7.55-7.50 (m, 3H), 7.47 (t, J = 8.0 Hz, 2H), 7.29 (dt, J = 8.8, 4.3 Hz, 1H), 7.23-7.19 (m, 4H), 7.19-7.14 (m, 1H), 7.04 (t, J = 7.9 Hz, 2H), 6.80-6.75 (m, 2H), 6.55 (s, 1H), 4.44 (d, J = 18.4 Hz, 1H), 4.03 (d, J = 18.4 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ 139.66, 133.49, 133.29, 133.13, 132.90, 131.94, 131.82, 131.64, 131.60, 128.89, 128.73, 128.44, 128.39, 128.29, 128.20, 128.13, 127.99, 127.81, 126.73, 126.51, 125.98, 122.49, 122.12, 89.16, 85.02, 83.83, 83.29, 53.92, 34.74.
1H NMR (600 MHz, CDCl3) δ 8.10-8.06 (m, 2H), 7.73- 7.69 (m, 2H), 7.60-7.55 (m, 3H), 7.54-7.48 (m, 4H), 7.47- 7.43 (m, 2H), 7.43-7.39 (m, 2H), 7.39-7.34 (m, 2H), 7.27 (d, J = 8.5 Hz, 2H), 6.35 (s, 1H), 4.16 (dd, J = 18.4, 2.6 Hz, 1H), 3.78 (dd, J = 18.4, 2.5 Hz, 1H), 1.92 (t, J = 2.5 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ 141.53, 140.22, 139.36, 135.67, 133.02, 132.09, 132.00, 129.04, 128.87, 127.11, 127.00, 121.04, 88.70, 83.93, 78.24, 72.80, 53.85, 33.87.
1H NMR (600 MHz, Chloroform-d) δ 8.11-8.06 (m, 2H), 7.66-7.61 (m, 2H), 7.52-7.48 (m, 1H), 7.44 (t, J = 7.6 Hz, 2H), 7.26-7.23 (m, 1H), 7.19 (t, J = 7.5 Hz, 1H), 7.15 (t, J = 7.8 Hz, 2H), 7.12-7.08 (m, 4H), 6.95-6.89 (m, 4H), 6.32 (s, 1H), 4.39 (d, J = 18.4 Hz, 1H), 3.97 (d, J = 18.4 Hz, 1H), 3.79 (s, 3H).
1H NMR (600 MHz, Chloroform-d) δ 8.05-8.01 (m, 2H), 7.67-7.64 (m, 2H), 7.59-7.55 (m, 1H), 7.52-7.48 (m, 2H), 7.41-7.38 (m, 2H), 7.37-7.34 (m, 1H), 7.23 (dd, J = 5.1, 1.2 Hz, 1H), 7.02 (dd, J = 3.7, 1.0 Hz, 1H), 6.93 (dd, J = 5.2, 3.6 Hz, 1H), 6.32 (s, 1H), 4.13 (dd, J = 18.5, 2.6 Hz, 1H), 3.71 (dd, J = 18.4, 2.5 Hz, 1H), 1.91 (t, J = 2.5 Hz, 1H).
1H NMR (600 MHz, Chloroform-d) δ 9.97 (s, 1H), 8.09- 7.99 (m, 2H), 7.78 (d, J = 8.1 Hz, 2H), 7.65 (d, J = 7.4 Hz, 2H), 7.58-7.53 (m, 1H), 7.49 (t, J = 7.9 Hz, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.35 (t, J = 7.0 Hz, 1H), 7.31 (d, J = 8.2 Hz, 2H), 6.33 (s, 1H), 4.17 (dd, J = 18.5, 2.6 Hz, 1H), 3.72 (dd, J = 18.5, 2.5 Hz, 1H), 1.92 (s, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.07-8.03 (m, 2H), 7.59 (d, J = 8.1 Hz, 2H), 7.55 (t, J = 7.4 Hz, 1H), 7.49 (t, J = 8.0 Hz, 2H), 7.40 (d, J = 8.5 Hz, 2H), 7.30 (t, J = 7.4 Hz, 1H), 7.28-7.24 (m, 2H), 7.20-7.16 (m, 2H), 6.28 (s, 1H), 4.15 (dd, J = 18.5, 2.6 Hz, 1H), 3.73 (dd, J = 18.5, 2.5 Hz, 1H), 1.89 (t, J = 2.5 Hz, 1H), 1.32 (s, 9H).
1H NMR (600 MHz, Chloroform-d) δ 8.04 (d, J = 7.4 Hz, 2H), 7.61-7.58 (m, 2H), 7.56 (d, J = 14.9 Hz, 1H), 7.49 (t, J = 7.7 Hz, 2H), 7.31 (t, J = 6.8 Hz, 1H), 7.28-7.24 (m, 4H), 7.17 (d, J = 7.0 Hz, 2H), 6.26 (s, 1H), 4.12 (dd, J = 18.4, 2.5 Hz, 1H), 3.74 (dd, J = 18.4, 2.5 Hz, 1H), 2.49 (s, 3H), 1.91 (t, J = 2.5 Hz, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.05-7.97 (m, 2H), 7.58-7.55 (m, 3H), 7.52-7.50 (m, 4H), 7.34-7.30 (m, 1H), 7.27 (t, J = 7.4 Hz, 2H), 7.17 (d, J = 7.0 Hz, 2H), 6.25 (s, 1H), 4.10 (dd, J = 18.4, 2.5 Hz, 1H), 3.78 (dd, J = 18.3, 2.5 Hz, 1H), 1.91 (t, J = 2.5 Hz, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.09-8.04 (m, 2H), 7.73-7.68 (m, 2H), 7.60-7.56 (m, 3H), 7.54-7.50 (m, 4H), 7.47-7.43 (m, 2H), 7.43-7.39 (m, 2H), 7.38-7.35 (m, 2H), 7.27 (d, J = 8.5 Hz, 2H), 6.35 (s, 1H), 4.16 (dd, J = 18.4, 2.6 Hz, 1H), 3.78 (dd, J = 18.4, 2.5 Hz, 1H), 1.92 (t, J = 2.5 Hz, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.17 (s, 1H), 8.10- 8.07 (m, 2H), 7.89-7.84 (m, 3H), 7.77-7.73 (m, 1H), 7.57 (t, J = 7.4 Hz, 1H), 7.53-7.48 (m, 4H), 7.36-7.32 (m, 1H), 7.32-7.28 (m, 2H), 7.24-7.22 (m, 2H), 6.47 (s, 1H), 4.16 (dd, J = 18.5, 2.6 Hz, 1H), 3.76 (dd, J = 18.5, 2.5 Hz, 1H), 1.86 (t, J = 2.5 Hz, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.09-8.05 (m, 2H), 7.77-7.74 (m, 2H), 7.64-7.59 (m, 4H), 7.59-7.55 (m, 1H), 7.52-7.48 (m, 2H), 7.45 (t, J = 7.7 Hz, 2H), 7.36 (t, J = 7.4 Hz, 1H), 7.34-7.30 (m, 1H), 7.28 (t, J = 7.3 Hz, 2H), 7.21 (d, J = 6.9 Hz, 2H), 6.36 (s, 1H), 4.18 (dd, J = 18.4, 2.6 Hz, 1H), 3.80 (dd, J = 18.4, 2.5 Hz, 1H), 1.91 (t, J = 2.5 Hz, 1H).
1H NMR (600 MHz, Chloroform-d) δ 7.78-7.73 (m, 2H), 7.43 (t, J = 7.5 Hz, 1H), 7.30-7.27 (m, 3H), 7.27-7.22 (m, 4H), 7.07 (t, J = 7.6 Hz, 1H), 6.93 (d, J = 7.5 Hz, 2H), 6.39 (s, 1H), 4.21 (dd, J = 10.2, 2.5 Hz, 2H), 2.50 (s, 6H), 2.16 (t, J = 2.4 Hz, 1H).
1H NMR (400 MHz, Chloroform-d) δ 7.98 (d, J = 7.6 Hz, 2H), 7.40 (t, J = 7.4 Hz, 1H), 7.30 (t, J = 7.8 Hz, 2H), 7.27- 7.21 (m, 2H), 7.21-7.05 (m, 9H), 7.00 (d, J = 7.5 Hz, 2H), 6.50 (s, 1H), 4.43 (d, J = 18.8 Hz, 1H), 4.28 (d, J = 18.8 Hz, 1H), 2.61 (s, 6H).
1H NMR (600 MHz, Chloroform-d) δ 8.04-7.99 (m, 1H), 7.85-7.82 (m, 2H), 7.53 (t, J = 7.3 Hz, 2H), 7.49-7.41 (m, 6H), 7.36-7.25 (m, 6H), 7.17 (d, J = 6.9 Hz, 2H), 6.40 (s, 1H), 4.08 (dd, J = 18.6, 2.5 Hz, 1H), 3.78 (dd, J = 18.6, 2.5 Hz, 1H), 1.94 (t, J = 2.5 Hz, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.14-8.06 (m, 2H), 7.81 (d, J = 8.5 Hz, 2H), 7.67-7.63 (m, 4H), 7.62-7.58 (m, 1H), 7.53 (t, J = 7.6 Hz, 2H), 7.48 (t, J = 7.7 Hz, 2H), 7.39 (t, J = 7.4 Hz, 1H), 7.18 (d, J = 8.1 Hz, 2H), 7.13 (d, J = 8.0 Hz, 2H), 6.40 (s, 1H), 4.21 (dd, J = 18.4, 2.5 Hz, 1H), 3.86 (dd, J = 18.4, 2.5 Hz, 1H), 2.63-2.58 (m, 2H), 1.96 (t, J = 2.5 Hz, 1H), 1.66 (dq, J = 14.8, 7.4 Hz, 2H), 0.97 (t, J = 7.3 Hz, 3H).
1H NMR (600 MHz, Chloroform-d) δ 8.13-8.02 (m, 2H), 7.65 (d, J = 9.4 Hz, 2H), 7.55-7.49 (m, 1H), 7.45 (t, J = 7.6 Hz, 2H), 7.27-7.25 (m, 3H), 7.22-7.18 (m, 1H), 7.17 (t, J = 7.8 Hz, 2H), 7.14-7.10 (m, 4H), 6.97-6.91 (m, 2H), 6.34 (s, 1H), 4.39 (d, J = 18.4 Hz, 1H), 4.02 (d, J = 18.4 Hz, 1H), 2.45 (s, 3H).
1H NMR (600 MHz, Chloroform-d) δ 8.15-8.07 (m, 2H), 7.82-7.75 (m, 2H), 7.55-7.51 (m, 1H), 7.48-7.41 (m, 4H), 7.39-7.34 (m, 1H), 7.29-7.25 (m, 1H), 7.21 (t, J = 8.2 Hz, 1H), 7.19-7.14 (m, 4H), 7.14-7.10 (m, 2H), 6.99- 6.91 (m, 2H), 6.41 (s, 1H), 4.45 (dd, J = 18.5, 4.4 Hz, 1H), 3.99 (dd, J = 18.4, 5.4 Hz, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.08-8.04 (m, 1H), 7.89-7.86 (m, 2H), 7.51 (t, J = 7.3 Hz, 2H), 7.47-7.39 (m, 7H), 7.32-7.29 (m, 3H), 7.22 (t, J = 7.5 Hz, 2H), 7.14- 7.11 (m, 4H), 7.05-7.00 (m, 4H), 6.40 (s, 1H), 4.31 (d, J = 18.7 Hz, 1H), 3.93 (d, J = 18.7 Hz, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.06-8.02 (m, 2H), 7.76-7.72 (m, 2H), 7.57-7.51 (m, 1H), 7.51-7.47 (m, 2H), 7.42-7.37 (m, 2H), 7.37-7.33 (m, 2H), 7.26-7.23 (m, 1H), 7.18-7.12 (m, 2H), 6.37 (s, 1H), 4.13 (dd, J = 18.4, 2.5 Hz, 1H), 3.82 (dd, J = 18.4, 2.6 Hz, 1H), 1.87 (t, J = 2.5 Hz, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.57 (d, J = 8.5 Hz, 1H), 8.16-8.05 (m, 3H), 7.92-7.87 (m, 2H), 7.68-7.63 (m, 1H), 7.57-7.52 (m, 1H), 7.52-7.46 (m, 2H), 7.46- 7.41 (m, 2H), 7.32-7.28 (m, 1H), 7.28-7.25 (m, 2H), 7.16- 7.09 (m, 2H), 7.06 (s, 1H), 4.14 (dd, J = 18.7, 2.5 Hz, 1H), 3.52 (dd, J = 18.6, 2.5 Hz, 1H), 1.78 (t, J = 2.5 Hz, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.14-8.08 (m, 2H), 7.75 (d, J = 7.9 Hz, 2H), 7.57 (d, J = 2.2 Hz, 1H), 7.49 (t, J = 7.4 Hz, 1H), 7.45-7.39 (m, 4H), 7.35 (t, J = 7.2 Hz, 1H), 7.24-7.21 (m, 2H), 7.17-7.08 (m, 5H), 6.85 (dd, J = 8.5, 1.6 Hz, 1H), 6.56 (dd, J = 2.2, 0.9 Hz, 1H), 6.38 (s, 1H), 4.44 (d, J = 18.4 Hz, 1H), 3.95 (d, J = 18.4 Hz, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.11-8.05 (m, 2H), 7.59 (d, J = 8.9 Hz, 2H), 7.51 (t, J = 8.1 Hz, 1H), 7.44 (t, J = 8.0 Hz, 2H), 7.22 (t, J = 6.9 Hz, 1H), 7.10 (dd, J = 23.9, 8.3 Hz, 4H), 6.98 (d, J = 8.6 Hz, 2H), 6.94-6.89 (m, 4H), 6.30 (s, 1H), 4.41 (d, J = 18.5 Hz, 1H), 3.94-3.90 (m, 3H), 1.80- 1.74 (m, 2H), 1.47-1.41 (m, 2H), 1.26 (s, 12H), 0.88 (s, 3H).
1H NMR (600 MHz, Chloroform-d) δ 8.07-8.02 (m, 2H), 7.73-7.66 (m, 2H), 7.59-7.54 (m, 1H), 7.52-7.46 (m, 2H), 7.41-7.37 (m, 2H), 7.36-7.33 (m, 1H), 7.11 (d, J = 8.3 Hz, 2H), 7.08 (d, J = 8.4 Hz, 2H), 6.31 (s, 1H), 4.12 (dd, J = 18.4, 2.6 Hz, 1H), 3.76 (dd, J = 18.7, 2.6 Hz, 1H), 2.60- 2.51 (m, 2H), 1.89 (t, J = 2.5 Hz, 1H), 1.66-1.60 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H).
1H NMR (600 MHz, Chloroform-d) δ 8.08 (d, J = 7.2 Hz, 2H), 7.83-7.78 (m, 1H), 7.76-7.71 (m, 4H), 7.68 (s, 1H), 7.57 (t, J = 7.4 Hz, 1H), 7.53-7.48 (m, 4H), 7.41 (t, J = 7.4 Hz, 2H), 7.37 (t, J = 7.3 Hz, 1H), 7.21 (dd, J = 8.4, 1.6 Hz, 1H), 6.37 (s, 1H), 4.18 (dd, J = 18.4, 2.5 Hz, 1H), 3.79 (dd, J = 18.4, 2.5 Hz, 1H), 1.91 (t, J = 2.5 Hz, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.14-8.10 (m, 2H), 7.78-7.75 (m, 2H), 7.54-7.50 (m, 1H), 7.47-7.40 (m, 4H), 7.39-7.35 (m, 1H), 7.29-7.25 (m, 1H), 7.20-7.14 (m, 4H), 6.83 (s, 1H), 6.54 (s, 2H), 6.39 (s, 1H), 4.46 (d, J = 18.5 Hz, 1H), 3.92 (d, J = 18.5 Hz, 1H), 2.13 (s, 6H).
1H NMR (400 MHz, Chloroform-d) δ 8.11 (d, J = 7.5 Hz, 2H), 7.88 (d, J = 8.3 Hz, 1H), 7.77-7.65 (m, 4H), 7.48- 7.27 (m, 6H), 7.26-7.10 (m, 4H), 7.08 (d, J = 2.6 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 6.38 (s, 1H), 4.54 (d, J = 18.5 Hz, 1H), 4.17 (d, J = 18.5 Hz, 1H), 3.70 (s, 3H).
1H NMR (600 MHz, Chloroform-d) δ 8.07-8.02 (m, 2H), 7.95-7.92 (m, 2H), 7.66 (d, J = 7.7 Hz, 2H), 7.58-7.53 (m, 1H), 7.49 (t, J = 7.7 Hz, 2H), 7.40 (t, J = 7.2 Hz, 2H), 7.36 (t, J = 7.4 Hz, 1H), 7.22 (d, J = 8.5 Hz, 2H), 6.33 (s, 1H), 4.17 (dd, J = 18.5, 2.5 Hz, 1H), 3.91 (s, 3H), 3.72 (dd, J = 18.5, 2.5 Hz, 1H), 1.90 (s, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.68-8.63 (m, 2H), 8.14-8.10 (m, 2H), 8.06 (d, J = 8.1 Hz, 1H), 7.83-7.78 (m, 3H), 7.70 (s, 1H), 7.69-7.66 (m, 2H), 7.63-7.59 (m, 1H), 7.57-7.53 (m, 1H), 7.53-7.50 (m, 1H), 7.49-7.43 (m, 4H), 7.42-7.37 (m, 1H), 6.53 (s, 1H), 4.26 (dd, J = 18.5, 2.5 Hz, 1H), 3.85 (dd, J = 18.4, 2.5 Hz, 1H), 1.89 (t, J = 2.5 Hz, 2H).
1H NMR (600 MHz, Chloroform-d) δ 8.07 (d, J = 6.5 Hz, 2H), 7.59-7.53 (m, 3H), 7.50 (t, J = 7.7 Hz, 2H), 7.33- 7.29 (m, 1H), 7.29-7.25 (m, 6H), 7.19 (d, J = 7.9 Hz, 2H), 7.12-7.08 (m, 6H), 7.05 (t, J = 7.7 Hz, 2H), 6.29 (s, 1H), 4.18 (d, J = 18.4 Hz, 1H), 3.87 (d, J = 18.4 Hz, 1H), 1.97 (s, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.18-8.13 (m, 2H), 8.11-8.06 (m, 1H), 8.00 (dd, J = 7.9, 1.1 Hz, 1H), 7.82- 7.78 (m, 3H), 7.49-7.41 (m, 7H), 7.37-7.34 (m, 1H), 7.20- 7.16 (m, 2H), 7.13-7.10 (m, 2H), 7.09-7.06 (m, 2H), 6.91 (dd, J = 7.4, 1.1 Hz, 1H), 6.42 (s, 1H), 4.58 (d, J = 18.4 Hz, 1H), 4.11 (d, J = 18.5 Hz, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.21-8.16 (m, 2H), 8.14-8.10 (m, 2H), 7.96 (dt, J = 7.5, 1.0 Hz, 1H), 7.95- 7.91 (m, 1H), 7.55-7.50 (m, 2H), 7.50-7.44 (m, 4H), 7.35- 7.31 (m, 1H), 7.30-7.26 (m, 2H), 7.19-7.16 (m, 2H), 6.67 (s, 1H), 4.21 (dd, J = 18.9, 2.8 Hz, 1H), 3.64 (dd, J = 18.6, 2.5 Hz, 1H), 1.80 (t, J = 2.5 Hz, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.04 (d, J = 7.2 Hz, 2H), 7.85 (d, J = 8.7 Hz, 2H), 7.66 (d, J = 8.2 Hz, 2H), 7.62- 7.58 (m, 1H), 7.55-7.50 (m, 2H), 7.37-7.32 (m, 1H), 7.32- 7.28 (m, 2H), 7.23-7.19 (m, 2H), 6.36 (s, 1H), 4.13 (dd, J = 18.3, 2.5 Hz, 1H), 3.84 (dd, J = 18.3, 2.6 Hz, 1H), 1.98- 1.87 (m, 1H).
1H NMR (600 MHz, Chloroform-d) δ 8.08-8.04 (m, 2H), 7.66 (d, J = 8.4 Hz, 2H), 7.59-7.54 (m, 1H), 7.52-7.48 (m, 2H), 7.43 (d, J = 8.3 Hz, 2H), 7.34-7.30 (m, 1H), 7.29- 7.26 (m, 2H), 7.22-7.18 (m, 2H), 6.73 (dd, J = 17.6, 10.9 Hz, 1H), 6.31 (s, 1H), 5.79 (dd, J = 17.6, 0.8 Hz, 1H), 5.35- 5.20 (m, 1H), 4.15 (dd, J = 18.7, 2.8 Hz, 1H), 3.78 (dd, J = 18.5, 2.5 Hz, 1H), 1.92 (t, J = 2.5 Hz, 1H).
1H NMR (400 MHz, Chloroform-d) δ 7.96 (d, J = 7.5 Hz, 2H), 7.61 (d, J = 7.3 Hz, 2H), 7.46 (t, J = 7.3 Hz, 1H), 7.39 (t, J = 7.5 Hz, 2H), 7.27 (dd, J = 11.3, 7.2 Hz, 3H), 6.23 (s, 1H), 4.05 (dd, J = 18.4, 2.3 Hz, 1H), 3.67 (dd, J = 18.4, 2.4 Hz, 1H), 1.81 (t, J = 2.4 Hz, 1H).
The compound PA-1 (0.5 mmol) and potassium carbonate (1.5 mmol) are added to a reaction tube, and 2 mL of isopropanol is added as a solvent. After reacting under nitrogen at 80° C. for 24 hours, the reaction solution is spin-dried and passed through a column to obtain the compound IM-1. The entire reaction and post-processing process must be kept in an oxygen-free state (yield 70%).
The NMR data of the product are as follows:
1H NMR (600 MHz, CDCl3) δ 8.29 (s, 1H), 8.10-8.01 (m, 3H), 7.99 (d, J=8.2 Hz, 1H), 7.94 (d, J=8.2 Hz, 1H), 7.61-7.57 (m, 4H), 7.55-7.52 (m, 1H), 5.14 (s, 2H). 13C NMR (151 MHz, CDCl3) δ 172.35, 146.57, 137.23, 134.91, 133.21, 132.73, 130.25, 129.37, 128.88, 128.33, 128.11, 127.26, 125.98, 121.98, 120.83, 63.91.
The high-resolution mass spectrometry data of the product are as follows:
HRMS m/z (ESI) calcd for [C18H13NH]([M+H]+): 244.1121, found: 244.1121.
The compound PA-2 (0.5 mmol) and potassium carbonate (1.5 mmol) are added to a reaction tube, and 2 mL of isopropanol is added as a solvent. After reacting for 24 hours under argon at 80° C., the reaction solution is spin-dried and passed through a column to obtain compound IM-2. The entire reaction and post-processing process must be kept in an oxygen-free state (yield 48%).
The NMR data of the product are as follows:
1H NMR (600 MHz, Chloroform-d) δ 8.27 (s, 1H), 8.04 (s, 1H), 7.98 (d, J=8.4 Hz, 3H), 7.93 (d, J=8.2 Hz, 1H), 7.59-7.56 (m, 1H), 7.54-7.51 (m, 1H), 7.44-7.42 (m, 2H), 2.57 (s, 3H).
The compound PA-1 (0.5 mmol) and cesium carbonate (1.5 mmol) are added to a reaction tube, and 2 mL of isopropanol is added as a solvent. After reacting under argon at 80° C. for 24 hours, the reaction solution is spin-dried and passed through a column to obtain compound IM-1. The entire reaction and post-processing process must be kept in an oxygen-free state (yield 62%).
The NMR data of the product are as follows:
1H NMR (600 MHz, CDCl3) δ 8.29 (s, 1H), 8.10-8.01 (m, 3H), 7.99 (d, J=8.2 Hz, 1H), 7.94 (d, J=8.2 Hz, 1H), 7.61-7.57 (m, 4H), 7.55-7.52 (m, 1H), 5.14 (s, 2H). 13C NMR (151 MHz, CDCl3) δ 172.35, 146.57, 137.23, 134.91, 133.21, 132.73, 130.25, 129.37, 128.88, 128.33, 128.11, 127.26, 125.98, 121.98, 120.83, 63.91.
The high-resolution mass spectrometry data of the product are as follows:
HRMS m/z (ESI) calcd for [C18H13NH]([M+H]+): 244.1121, found: 244.1121.
The compound PA-1 (0.5 mmol) and potassium carbonate (1.5 mmol) are added to a reaction tube, and 2 mL of n-butanol is added as a solvent. After reacting under nitrogen at 120° C. for 24 hours, the reaction solution is spin-dried and passed through a column to obtain compound IM-1. The entire reaction and post-processing process must be kept in an oxygen-free state (yield 82%).
The NMR data of the product are as follows:
1H NMR (600 MHz, CDCl3) δ 8.29 (s, 1H), 8.10-8.01 (m, 3H), 7.99 (d, J=8.2 Hz, 1H), 7.94 (d, J=8.2 Hz, 1H), 7.61-7.57 (m, 4H), 7.55-7.52 (m, 1H), 5.14 (s, 2H). 13C NMR (151 MHz, CDCl3) δ 172.35, 146.57, 137.23, 134.91, 133.21, 132.73, 130.25, 129.37, 128.88, 128.33, 128.11, 127.26, 125.98, 121.98, 120.83, 63.91.
The high-resolution mass spectrometry data of the product are as follows:
HRMS m/z (ESI) calcd for [C18H13NH]([M+H]+): 244.1121, found: 244.1121.
Compound PA-2 (0.5 mmol) and potassium carbonate (1.5 mmol) are added to a reaction tube, and 2 mL of isopropanol is added as a solvent. After reacting under nitrogen at 80° C. for 24 hours, the reaction solution is spin-dried and passed through a column to obtain compound IM-2. The entire reaction and post-processing process must be kept in an oxygen-free state (yield 78%).
The NMR data of the product are as follows:
1H NMR (600 MHz, Chloroform-d) δ 8.27 (s, 1H), 8.04 (s, 1H), 7.98 (d, J=8.4 Hz, 3H), 7.93 (d, J=8.2 Hz, 1H), 7.59-7.56 (m, 1H), 7.54-7.51 (m, 1H), 7.44-7.42 (m, 2H), 2.57 (s, 3H).
The compound IM-1 (0.2 mmol) is dissolved in 1 mL of isopropanol solvent, oxygen in the air is used as an oxidant, and the mixture is reacted at 80° C. for 24 hours. After the reaction is completed, the reaction solution is spin-dried and passed through a column to obtain the dimer compound FL-1. (Yield 38%).
The NMR data of the product FL-1 are as follows:
1H NMR (400 MHz, CDCl3) δ 9.49 (s, 2H), 8.45-8.40 (m, 4H), 8.36 (s, 2H), 8.12 (d, J=7.8 Hz, 2H), 7.99 (d, J=7.8 Hz, 2H), 7.73-7.65 (m, 6H), 7.62-7.55 (m, 4H).
13C NMR (150 MHz, CDCl3) δ 170.75, 148.39, 137.13, 135.36, 134.99, 133.73, 133.16, 131.12, 130.06, 129.90, 129.26, 129.06, 127.86, 127.49, 126.96, 122.98.
The high-resolution mass spectrometry data of the product are as follows:
HRMS m/z (ESI) calcd for [C36H22N2H]([M+H]+): 483.1856, found: 483.1855.
The compound IM-2 (0.2 mmol) is dissolved in 1 mL of isopropanol solvent, and 2,2,6,6-tetramethylpiperidinium N-oxide (TEMPO, 2 equiv.) is added and reacted at 80° C. for 24 hours. After the reaction is completed, the reaction solution is spin-dried and passed through a column to obtain the dimer compound FL-2. (Yield 18%).
The NMR data of the product FL-2 are as follows:
1H NMR (400 MHz, CDCl3/CF3COOD, 5:1) δ 9.54 (s, 2H), 9.07 (s, 2H), 8.31 (d, J=8.3 Hz, 4H), 8.26 (d, J=8.2 Hz, 4H), 8.02 (t, J=7.5 Hz, 2H), 7.95 (t, J=7.5 Hz, 2H), 7.64 (d, J=8.1 Hz, 4H), 2.71 (s, 6H).
13C NMR (150 MHz, CDCl3/CF3COOD, 5:1) δ 166.84, 156.87, 136.41, 134.55, 134.14, 133.21, 131.97, 131.70, 131.49, 131.12, 130.76, 128.61, 128.23, 128.01, 126.65, 120.88, 14.57.
The high-resolution mass spectrometry data of the product FL-2 are as follows:
HRMS m/z (ESI) calcd for [C38H26N2S2Na]([M+Na]+): 597.1430, found: 597.1427.
The compound IM-3 (0.2 mmol) is dissolved in 1 mL of isopropanol solvent, and 8% sodium hypochlorite aqueous solution (2 equiv.) is added, and the mixture is reacted at 80° C. for 24 hours. After the reaction is completed, the reaction solution is spin-dried and passed through a column to obtain the dimer compound FL-3. (Yield 68%).
The NMR data of the product FL-3 are as follows:
1H NMR (600 MHz, CDCl3/CF3COOD, 5:1) δ 9.50 (s, 2H), 9.00 (s, 2H), 8.43 (d, J=8.8 Hz, 4H), 8.26 (d, J=8.3 Hz, 4H), 7.96 (t, J=7.6 Hz, 2H), 7.90 (t, J=7.5 Hz, 2H), 7.59 (d, J=8.8 Hz, 4H), 3.48 (s, 12H).
13C NMR (150 MHz, CDCl3/CF3COOD, 5:1) δ 159.69, 152.52, 136.01, 134.37, 134.23, 133.89, 132.47, 132.32, 131.42, 131.21, 131.01, 130.24, 128.93, 128.18, 127.01, 119.17, 44.11. IR (thin film) v 1433, 1455, 1598, 2850, 2919 cm−1.
The high-resolution mass spectrometry data of the product FL-3 are as follows:
HRMS m/z (ESI) calcd for [C40H32N4H]([M+H]+): 569.2700, found: 569.2708.
The compound IM-4 (0.2 mmol) is dissolved in 1 mL of isopropanol solvent, and a 30% aqueous hydrogen peroxide solution (2 equiv.) is added and reacted at 80° C. for 24 hours. After the reaction is completed, the reaction solution is spin-dried and passed through a column to obtain the dimer compound FL-4. (Yield 22%).
The NMR data of the product FL-4 are as follows:
11H NMR (600 MHz, CDCl3) δ 9.47 (s, 2H), 8.41 (d, J=8.2 Hz, 4H), 8.37 (s, 2H), 8.11 (d, J=8.0 Hz, 2H), 7.98 (d, J=7.9 Hz, 2H), 7.71 (d, J=8.1 Hz, 4H), 7.59 (t, J=7.2 Hz, 2H), 7.55 (t, J=7.9 Hz, 2H), 6.88 (dd, J=17.6, 10.8 Hz, 2H), 5.97 (d, J=17.6 Hz, 2H), 5.43 (d, J=10.9 Hz, 2H).
13C NMR (150 MHz, CDCl3) δ 169.99, 148.39, 140.24, 137.18, 136.51, 135.35, 134.35, 133.69, 133.13, 130.03, 129.89, 129.48, 127.78, 127.49, 126.96, 126.85, 122.95, 115.76. IR (thin film) v 1474, 1500, 1603, 1623, 2849, 2918 cm−1.
The high-resolution mass spectrometry data of the product FL-4 are as follows:
HRMS m/z (ESI) calcd for [C40H26N2H]([M+H]+): 535.2169, found: 535.2169.
The compound IM-5 (0.2 mmol) is dissolved in 1 mL of isopropanol solvent and reacted at 80° C. for 24 hours in an atmosphere of oxygen in air as an oxidant. After the reaction is completed, the reaction solution is spin-dried and passed through a column to obtain the dimer compound FL-5. (Yield 22%).
The NMR data of the product FL-5 are as follows:
1H NMR (400 MHz, CDCl3) δ 9.37 (s, 2H), 8.39 (d, J=7.6 Hz, 4H), 8.18 (s, 2H), 7.94 (s, 2H), 7.88 (d, J=8.5 Hz, 2H), 7.71-7.66 (m, 8H), 6.94 (dd, J=17.6, 10.9 Hz, 2H), 5.96 (d, J=17.6 Hz, 2H), 5.43 (d, J=10.8 Hz, 2H).
13C NMR (150 MHz, CDCl3) δ 170.61, 148.42, 137.55, 136.89, 136.59, 135.29, 134.97, 133.83, 132.74, 131.07, 130.07, 129.27, 129.02, 128.49, 127.96, 124.17, 122.64, 115.04. IR (thin film) v 1445, 1473, 2980, 3006, 3050 cm−1.
The high-resolution mass spectrometry data of the product FL-5 are as follows:
HRMS m/z (ESI) calcd for [C40H26N2H]([M+H]+): 535.2169, found: 535.2169.
The compound IM-6 (0.2 mmol) is dissolved in 1 mL of isopropanol solvent and reacted under an oxygen atmosphere at 120° C. for 24 hours. After the reaction is completed, the reaction solution is spin-dried and passed through a column to obtain the dimer compound FL-6. (Yield 42%).
The NMR data of the product FL-6 are as follows:
1H NMR (400 MHz, CDCl3) δ 9.42 (s, 2H), 8.43 (d, J=7.2 Hz, 4H), 8.31 (s, 2H), 7.95-7.86 (m, 4H), 7.73-7.62 (m, 6H), 7.41 (d, J=8.2 Hz, 2H), 2.83 (t, J=7.6 Hz, 4H), 1.87-1.73 (m, 4H), 1.03 (t, J=7.3 Hz, 6H).
13C NMR (150 MHz, CDCl3) δ 170.79, 148.44, 142.25, 137.30, 135.13, 134.78, 134.00, 131.63, 131.00, 129.71, 129.24, 129.03, 128.69, 128.66, 127.47, 122.77, 38.40, 24.54, 14.00.
The high-resolution mass spectrometry data of the product FL-6 are as follows:
HRMS m/z (ESI) calcd for [C42H34N2H]([M+H]+): 567.2795, found: 567.2795.
The compound IM-7 (0.2 mmol) is dissolved in 1 mL of p-xylene solvent and reacted under an oxygen atmosphere at 80° C. for 24 hours. After the reaction is completed, the reaction solution is spin-dried and passed through a column to obtain the dimer compound FL-7. (Yield 33%).
The NMR data of the product FL-7 are as follows:
1H NMR (400 MHz, CDCl3/CF3COOD, 5:1) δ 10.30 (s, 2H), 8.86 (d, J=8.1 Hz, 2H), 8.73 (s, 2H), 8.71-8.65 (m, 4H), 8.54 (d, J=8.1 Hz, 2H), 7.80-7.71 (m, 6H), 7.68 (t, J=7.5 Hz, 2H), 7.58 (t, J=7.7 Hz, 2H), 7.42 (d, J=7.7 Hz, 4H), 2.45 (s, 12H).
13C NMR (100 MHz, CDCl3/CF3COOD, 5:1) δ 177.99, 137.03, 134.76, 134.18, 133.70, 132.22, 131.19, 130.97, 129.55, 129.19, 129.10, 129.03, 128.53, 128.34, 127.87, 125.06, 124.86, 123.84, 123.71, 123.47, 121.42, 20.55.
The high-resolution mass spectrometry data of the product FL-7 are as follows:
HRMS m/z (ESI) calcd for [C56H38N2H]([M+H]+): 739.3108, found: 739.3108.
The compound IM-8 (0.1 mmol) and IM-1 (0.1 mmol) are dissolved in 1 mL of isopropanol solvent and reacted under an oxygen atmosphere at 80° C. for 24 hours. After the reaction is completed, the reaction solution is spin-dried and passed through a column to obtain the heterodimeric compound FL-8. (Yield 21%).
The NMR data of the product FL-8 are as follows:
1H NMR (600 MHz, CDCl3) δ 9.46 (s, 1H), 9.42 (s, 1H), 8.43-8.41 (m, 2H), 8.37-8.33 (m, 4H), 8.09 (d, J=7.3 Hz, 1H), 7.97 (d, J=8.3 Hz, 1H), 7.88-7.84 (m, 2H), 7.70-7.67 (m, 2H), 7.65-7.61 (m, 1H), 7.57-7.51 (m, 2H), 7.40-7.35 (m, 5H), 7.29-7.25 (m, 6H), 7.18-7.14 (m, 2H), 2.84-2.80 (m, 2H), 1.77-1.72 (m, 2H), 1.40-1.27 (m, 10H), 0.87 (t, J=7.1 Hz, 3H).
13C NMR (150 MHz, CDCl3) δ 169.83, 169.57, 150.80, 149.01, 147.19, 147.05, 142.45, 137.52, 137.30, 135.31, 135.22, 134.86, 133.93, 133.65, 133.01, 131.60, 130.82, 130.46, 130.00, 129.83, 129.68, 129.20, 129.01, 128.59, 128.57, 127.88, 127.44, 127.36, 127.27, 126.71, 125.78, 124.31, 122.87, 122.68, 121.69, 36.38, 32.00, 31.50, 29.65, 29.52, 29.40, 22.78, 14.23.
The high-resolution mass spectrometry data of the product FL-8 are as follows:
HRMS m/z (ESI) calcd for [C56H47N3H]([M+H]+): 762.3843, found: 762.3846.
The compound IM-9 (0.2 mmol) is dissolved in 1 mL of p-xylene solvent and reacted under an oxygen atmosphere at 80° C. for 24 hours. After the reaction is completed, the reaction solution is spin-dried and passed through a column to obtain the dimer compound FL-9. (Yield 52%).
The NMR data of the product FL-9 are as follows:
1H NMR (600 MHz, CDCl3) δ 8.16 (s, 2H), 8.01 (s, 2H), 7.86 (d, J=8.7 Hz, 2H), 7.78 (d, J=8.8 Hz, 4H), 7.67-7.62 (m, 4H), 7.47-7.42 (m, 6H), 7.27 (t, J=8.2 Hz, 2H), 6.99 (d, J=8.8 Hz, 4H), 4.06 (t, J=6.6 Hz, 4H), 1.87-1.82 (m, 4H), 1.52-1.48 (m, 4H), 1.39-1.29 (m, 24H), 0.89 (t, J=7.0 Hz, 6H).
13C NMR (151 MHz, CDCl3) δ 164.46, 161.29, 150.00, 139.80, 138.12, 136.77, 136.04, 133.64, 133.34, 131.79, 131.31, 131.02, 130.94, 128.60, 127.54, 127.21, 126.85, 126.47, 122.70, 114.33, 68.30, 32.01, 29.70, 29.68, 29.52, 29.44, 29.33, 26.15, 22.79, 14.24.
The high-resolution mass spectrometry data of the product FL-9 are as follows:
HRMS m/z (ESI) calcd for [C68H68Cl2N2O2Na]([M+Na]+): 1037.4550, found: 1037.4550.
Cell line: L929 cells (mouse fibroblasts).
Cell culture: Cells are cultured in a CO2 incubator (37° C., 5% CO2) with DMEM medium (penicillin (100 U/mL) and streptomycin (100 μg/mL)).
Cell imaging experiment: Cells are cultured on 15 mm grade bottom cell culture dishes. Before labeling the cells with the probe, the culture medium is removed, and the cells are washed twice with Hank's buffer solution to remove the remaining culture medium. Then, 200 μL of probe IM-1 (10 μM) is added to the culture dish, and the cells are incubated in the dark for 30 minutes. The cells are washed twice with Hank's buffer solution to remove any remaining probe, and then 1 mL of Hank's solution is added to the culture dish. The cells are observed under a laser confocal microscope with a 100× objective. The excitation wavelength is 543 nm, and the emission wavelength is 550-600 nm. It was found that the probe labels the lysosomes and lysosomal autolysosomes in the cells, indicating that this compound can fluorescently label lysosomes and lysosomal autolysosomes in cells.
Example 17 Fluorescent labeling of L292 cells by IM-2
Cell line: L929 cells (mouse fibroblasts).
Cell culture: Cells are cultured in a CO2 incubator (37° C., 5% CO2) with DMEM medium (penicillin (100 U/mL) and streptomycin (100 μg/mL)).
Cell imaging experiment: Cells are cultured on 15 mm grade bottom cell culture dishes. Before labeling the cells with the probe, the culture medium is removed, and the cells are washed twice with Hank's buffer solution to remove the remaining culture medium. Then, 200 μL of probe IM-2 (5 μM) is added to the culture dish, and the cells are incubated in the dark for 30 minutes. The cells are washed twice with Hank's buffer solution to remove any remaining probe, and then 1 mL of Hank's solution is added to the culture dish. The cells are observed under a laser confocal microscope with a 100× objective. The excitation wavelength is 543 nm, and the emission wavelength is 550-600 nm. It was found that the probe labels the lysosomes and lysosomal autolysosomes in the cells, indicating that this compound can fluorescently label lysosomes and lysosomal autolysosomes in cells.
Cell line: L929 cells (mouse fibroblasts).
Cell culture: Cells are cultured in a CO2 incubator (37° C., 5% CO2) with DMEM medium (penicillin (100 U/mL) and streptomycin (100 μg/mL)).
Cell imaging experiment: Cells are cultured on 15 mm grade bottom cell culture dishes. Before labeling the cells with the probe, the culture medium is removed, and the cells are washed twice with Hank's buffer solution to remove the remaining culture medium. Then, 200 μL of probe IM-3 (2 μM) is added to the culture dish, and the cells are incubated in the dark for 30 minutes. The cells are washed twice with Hank's buffer solution to remove any remaining probe, and then 1 mL of Hank's solution is added to the culture dish. The cells are observed under a laser confocal microscope with a 100× objective. The excitation wavelength is 488 nm, and the emission wavelength is 600-650 nm. It was found that the probe labels the lysosomes and lysosomal autolysosomes in the cells, indicating that this compound can fluorescently label lysosomes and lysosomal autolysosomes in cells.
Cell line: L929 cells (mouse fibroblasts).
Cell culture: Cells are cultured in a CO2 incubator (37° C., 5% CO2) with DMEM medium (penicillin (100 U/mL) and streptomycin (100 μg/mL)).
Cell imaging experiment: Cells are cultured on 15 mm grade bottom cell culture dishes. Before labeling the cells with the probe, the culture medium is removed, and the cells are washed twice with Hank's buffer solution to remove the remaining culture medium. Then, 200 μL of probe MP-1 (10 μM) is added to the culture dish, and the cells are incubated in the dark for 30 minutes. The cells are washed twice with Hank's buffer solution to remove any remaining probe, and then 1 mL of Hank's solution is added to the culture dish. The cells are observed under a laser confocal microscope with a 100× objective. The excitation wavelength is 543 nm, and the emission wavelength is 550-600 nm. As shown in
Cell line: L929 cells (mouse fibroblasts).
Cell culture: Cells are cultured in a CO2 incubator (37° C., 5% CO2) with DMEM medium (penicillin (100 U/mL) and streptomycin (100 μg/mL)).
Cell imaging experiment: Cells are cultured on 15 mm grade bottom cell culture dishes. Before labeling the cells with the probe, the culture medium is removed, and the cells are washed twice with Hank's buffer solution to remove the remaining culture medium. Then, 200 μL of probe MP-2 (20 μM) is added to the culture dish, and the cells are incubated in the dark for 30 minutes. The cells are washed twice with Hank's buffer solution to remove any remaining probe, and then 1 mL of Hank's solution is added to the culture dish. The cells are observed under a laser confocal microscope with a 100× objective. The excitation wavelength is 488 nm, and the emission wavelength is 500-540 nm. As shown in
Cell line: RAW 264.7 cell (mouse mononuclear macrophage leukemia cell); SKBR3 cell (HER2-breast cancer overexpressing cell); HuH-7 cell (human hepatoma cell line).
Cell culture: Cells are cultured in a CO2 incubator (37° C., 5% CO2) with DMEM medium (penicillin (100 U/mL) and streptomycin (100 μg/mL)).
Cell imaging experiment: three types of cells are cultured on 15 mm grade bottom cell culture dishes. Before labeling the cells with the probe, the culture medium is removed, and the cells are washed twice with Hank's buffer solution to remove the remaining culture medium. Then, 200 μL of probe MP-1 (10 μM) is added to the culture dish, and the cells are incubated in the dark for 30 minutes. The cells are washed twice with Hank's buffer solution to remove any remaining probe, and then 1 mL of Hank's solution is added to the culture dish. The cells are observed under a laser confocal microscope with a 100× objective. As shown in
Cells are cultured in imaging culture dishes for 6 h and then treated with cytc-290 (designed silent siRNA) or nontargeting RNA. After a certain period of action, live cell imaging is performed under a confocal laser scanning microscope. After 12 hours of ctyc-290 treatment, Hoechst 33342 and MTG staining are good, but about 10% of the cells could not be labeled by MP-1. About 30% of the cells could not be labeled by MP-1 after 18 hours of treatment with ctyc-290. As shown in
The cells are cultured in the imaging culture dish for 6 h, and then treated with cytc-436 (designed silent siRNA) or non-targeting RNA for a certain period of time, and then live cell imaging is performed under a confocal laser scanning microscope. After 6 hours of ctyc-436 treatment, Hoechst 33342 and MTG staining are good, but about 5% of the cells could not be labeled by MP-1. In contrast, the staining effect of MP-1 in the control group using non-targeting RNA is still good. The results show that the probe MP-1 can effectively reflect the activity of the respiratory chain and can be used to detect the absence of enzymes in the respiratory chain.
Take the L292 cells of Example 19, remove all the culture medium, add 8 ml of deionized water, and allow the cells to absorb water and burst for about 1 hour. The broken liquid is then collected, ultrasonicated at 20 kHz for 10 minutes, vortexed at 2500 rpm for 10 minutes, and finally extracted with dichloromethane. The organic phase is taken out and then 1/1000 trifluoroacetic acid is added for mass spectrometry analysis. From
The compound PA-1 is dissolved in dichloromethane and applied to five pieces of polytetrafluoroethylene carriers respectively, then sodium hypochlorite aqueous solutions with different concentrations (8% mass concentration of sodium hypochlorite aqueous solution, 50 times diluted solution, 500 times diluted solution, 500 times diluted solution, and NaClO-free aqueous solution) are dripped on the carriers. Then, heat at 100° C. for 30 seconds. The carrier will change from colorless to red, and under 365 nm ultraviolet light, the fluorescence will gradually change from no fluorescence to strong fluorescence.
A typical test result is shown in
The fluorescence performance of the benzisoindole dimer compound is tested. with the specific testing method as follows: accurately weigh 1 mg of the sample and dissolve it in 10 mL of tetrahydrofuran. First, the absorption spectrum of the compound is measured, and the maximum absorption wavelength is used to measure the emission spectrum of the compound. The maximum emission wavelength can be obtained through the emission spectrum, and the optimal excitation wavelength of the maximum emission wavelength test compound can be selected. By selecting the optimal excitation wavelength to excite the compound, the final emission spectrum can be obtained.
Typical test results are shown in
This indicates that s this type of compound has potential applications in fluorescence materials, fluorescence probes, etc.
The electrical properties of the benzisoindole dimer compounds are tested, with the specific testing method as follows: tetrabutylammonium hexafluorophosphate is used as the electrolyte at a concentration of 0.1M, and 5 mL of tetrahydrofuran is used as the solvent. The glassy carbon electrode is used as the working electrode, the platinum wire electrode is used as the auxiliary electrode, and the saturated calomel electrode is used as the reference electrode, with a scan rate of 100 mV/s.
The typical test result is shown in
This indicates that this type of compound has two reduced states and may be used as conductive organic compounds or photo-redox catalysts.
The above are only a few Examples of the present application and do not constitute any form of limitation to the present application. Although the present application is disclosed as above with preferred embodiments, it is not intended to limit the present application. The person skilled in the art, without departing from the scope of the technical solution of the present application, using the technical content disclosed above to make slight changes or modifications are equivalent to equivalent implementation cases and fall within the scope of the technical solution.
| Number | Date | Country | Kind |
|---|---|---|---|
| 202210208626.6 | Mar 2022 | CN | national |
| 202210209603.7 | Mar 2022 | CN | national |
| 202210209604.1 | Mar 2022 | CN | national |
| 202210218223.X | Mar 2022 | CN | national |
This application is the national phase entry of International Application No. PCT/CN2022/138827, filed on Dec. 13, 2022, which is based upon and claims priority to Chinese Patent Application No. 202210209604.1, filed on Mar. 4, 2022, to Chinese Patent Application No. 202210208626.6, filed on Mar. 4, 2022, to Chinese Patent Application No. 202210218223.X, filed on Mar. 4, 2022, and to Chinese Patent Application No. 202210209603.7, filed on Mar. 4, 2022, the entire contents of which are incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2022/138827 | 12/13/2022 | WO |
